This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
Stocks Under $10 with 50-100% upside potential - 14 days FREE!

Cubist Pharmaceuticals Appoints Jane Henney To Board Of Directors

Cubist Pharmaceuticals, Inc. (NASDAQ: CBST) today announced the appointment of Jane E. Henney, M.D. to its Board of Directors. Dr. Henney currently is a Professor of Medicine at the University of Cincinnati College of Medicine. With the addition of Dr. Henney, the Cubist Board of Directors consists of 11 members, 10 of whom are independent.

“Jane brings a tremendous breadth of experience from her career, and we are delighted to welcome her to our Board,” said Kenneth Bate, non-executive Chairman of the Board of Directors of Cubist. “The medical and health policy insights Jane has gained over her years as FDA Commissioner and as a leader of large and successful medical organizations will prove invaluable to Cubist as we continue to grow and expand our acute care business.”

In addition to serving as a Professor of Medicine from 2003-2008, Dr. Henney also served as the Senior Vice President and Provost of University of Cincinnati’s Academic Health Center. In 2008 Dr. Henney was appointed to her current position as a Professor of Medicine at the University of Cincinnati College of Medicine. Dr. Henney served as the Senior Scholar at the Association of Academic Health Centers (AAHC) from 2001-2003. Before joining the AAHC, Dr. Henney served as the Commissioner of the U.S. Food and Drug Administration (FDA) from 1998-2001. From 1994-1998 she was Vice President for Health Sciences at the University of New Mexico. Dr. Henney worked at the FDA as Deputy Commissioner of Operations from 1992-1994. Before her time at the FDA, Dr. Henney served in a variety of senior leadership positions, including interim Dean of the College of Medicine at the University of Kansas School of Medicine. Prior to this position, Dr. Henney held a variety of positions at the National Cancer Institute including Deputy Director from 1980-1985. From 1976-1985, Dr. Henney served in a variety of roles at the National Institutes of Health (NIH), eventually becoming its Deputy Director in 1982. Dr. Henney received her undergraduate degree from Manchester College, her medical degree from Indiana University and her training in Oncology from M.D. Anderson Hospital and Tumor Institute. She currently sits on the board of directors for both AmerisourceBergen Corporation and CIGNA Corporation.

1 of 2

Select the service that is right for you!

COMPARE ALL SERVICES
Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!
DOW 16,960.57 -123.23 -0.72%
S&P 500 1,978.34 -9.64 -0.48%
NASDAQ 4,449.5640 -22.5440 -0.50%

Brokerage Partners

Rates from Bankrate.com

  • Mortgage
  • Credit Cards
  • Auto

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs